What are examples of alginate‑antacid combination medications (e.g., Gaviscon Double‑Action (sodium alginate/potassium bicarbonate/calcium carbonate), Gaviscon Original (sodium alginate/calcium carbonate), Gaviscon Advance (sodium alginate/calcium carbonate), Algicon (sodium alginate/calcium carbonate))?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Alginate-Antacid Combination Medications

The most commonly available alginate-antacid combination medications include Gaviscon Advance (sodium alginate/potassium bicarbonate), Gaviscon Double Action (sodium alginate/potassium bicarbonate/calcium carbonate), and Gaviscon Original (sodium alginate/sodium bicarbonate/calcium carbonate).

Available Formulations

The primary alginate-antacid products on the market are variations of the Gaviscon brand 1:

  • Gaviscon Advance: Contains sodium alginate with potassium bicarbonate as the primary formulation
  • Gaviscon Double Action: Contains sodium alginate combined with both potassium bicarbonate and calcium carbonate
  • Gaviscon Original: Contains sodium alginate with sodium bicarbonate and calcium carbonate

These products are available in both liquid and chewable tablet formulations 2, 3.

Clinical Context and Use

Alginate-antacid combinations should be used as adjunctive therapy for breakthrough GERD symptoms, particularly post-prandial and nighttime symptoms, rather than as first-line monotherapy 4.

Mechanism of Action

These medications work through a dual mechanism:

  • The alginate component forms a physical "raft" barrier that floats on top of gastric contents, displacing the postprandial acid pocket below the diaphragm 5
  • The antacid component (bicarbonate/carbonate salts) provides immediate acid neutralization 6

Evidence-Based Indications

According to current guidelines, alginate-antacids should be personalized to specific GERD phenotypes 4:

  • Breakthrough symptoms in patients already on PPI therapy
  • Post-prandial symptoms (particularly effective due to acid pocket suppression)
  • Nighttime reflux symptoms
  • Patients with hiatal hernias (the raft mechanism is particularly beneficial in this population) 4

Clinical Efficacy

Research demonstrates that Gaviscon Advance and Gaviscon Double Action significantly reduce esophageal acid exposure compared to placebo 2, 3, 7. When added to PPI therapy, these agents provide additional symptom relief beyond acid suppression alone 8, 3.

Important caveat: While alginate-antacids show superiority over placebo in reducing acid exposure and symptoms, the clinical response can be variable, with some studies showing high placebo response rates in functional symptoms 8. This underscores the importance of using these agents in patients with objectively documented GERD rather than empirically.

Formulation Differences

Gaviscon Double Action has been shown to have significantly superior alginate content within the raft structure compared to competitor products (p < 0.0001), with optimal porosity allowing for longer duration of acid neutralization 6. This may translate to better clinical efficacy, though head-to-head comparisons between different Gaviscon formulations are limited.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.